Gene Therapy: AAV Doses Should Not Be Subject To Fixed Upper Limit, US FDA Panel Says

 
• By Sue Sutter
  
Dime
Manufacturers cannot just "turn on a dime" and make a new lot of AAV gene therapy with much greater purity, the FDA acknowledges. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers